HER2 Positive Breast Cancers Drastically Reduced Before Surgery with 2-Drug Combo, Study Shows

HER2 Positive Breast Cancers Drastically Reduced Before Surgery with 2-Drug Combo, Study Shows
A clinical trial funded by Cancer Research UK indicates that a drug combination of lapatinib, a protein tyrosine kinase inhibitor, and trastuzumab, a monoclonal antibody, before surgery can quickly shrink and even destroy tumors in women with HER2-positive breast cancer. The results were presented earlier this month at the 10th European Breast Cancer Conference in Amsterdam. HER-2 (human epidermal growth factor receptor 2is a cell-surface protein involved in the control of cell growth. HER2-positive is used to describe cancer cells that express high levels of this protein, leading to abnormal tumor growth and increased metastatic potential. HER-2 positive cancers are also more likely to return after treatment than other breast cancers. Treatment includes surgery, chemotherapy, endocrine therapy, and targeted anti-HER2 drugs. Both lapatinib and trastuzumab are approved as single or conjugation therapies for the treatment of HER2-positive breast cancer. Leading the EPHOS B clinical trial were researchers at The Institute of Cancer Research in London, the University of Manchester, and University Hospital of South Manchester NHS Foundation Trust. They investigated the possible changes in HER-2 po
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.